Table 3.
Characteristics of patients included in analyses of attrition and mortality at initiation of ART
| Total—n | 432 |
|---|---|
| Registered within KHDSS—n (%) | 398 (92) |
| Route of HIV testing—n (%) | |
| CRH | 203 (47) |
| HIV serosurvey | 181 (42) |
| Missing | 48 (11) |
| Sex—n (%) | |
| Male | 189 (44) |
| Female | 243 (56) |
| Age—n (%) | |
| 15–34 | 162 (38) |
| ≥35 | 270 (63) |
| Median age—years | 38.0 |
| Weight—kg | |
| Median (IQR) | 52.9 (46.8–58.4) |
| Missing—n (%) | 12 (3) |
| Median BMI | 20.1 |
| Year of ART initiation—n (%) | |
| 2008 | 150 (35) |
| 2009 | 106 (25) |
| 2010 | 117 (27) |
| 2011 | 59 (14) |
| WHO stage—n (%) | |
| 1 | 49 (11) |
| 2 | 134 (31) |
| 3 | 203 (47) |
| 4 | 46 (11) |
| CD4 count—n (%) cells/μL | |
| ≤250 | 285 (66) |
| 251–350 | 33 (8) |
| 351–500 | 14 (3) |
| >500 | 9 (2) |
| Missing | 91 (21) |
| Median CD4 count—cells/μL (IQR) | |
| Overall | 156 (77–227) |
| By route of HIV testing | |
| CRH | 139 (62–222) |
| HIV serosurvey | 167 (108–227) |
| Missing | 169 (69–244) |
| Starting Regimen—n (%) | |
| d4T-3TC-NVPa | 431 (99.8) |
| TDF-3TC-EFVb | 1 (0.2) |
| Clinical Details—n (%) | |
| Weight loss >10 % | 107 (25) |
| Oral candidiasis | 74 (17) |
| Severe bacterial infection | 72 (17) |
| Unexplained fever >1 month | 32 (7) |
| Wasting syndrome | 14 (3) |
| Pulmonary tuberculosis | 12 (3) |
| Kaposi’s sarcoma | 10 (2) |
| Oesophageal candidiasis | 9 (2) |
| Extrapulmonary tuberculosis | 5 (1) |
aStavudine, lamivudine and nevirapine
bTenofovir disoproxil fumarate, lamivudine and efavirenz